Prostate Cancer Treatment Response with Artificial Intelligence: A Literature Review

Raquel Lopes

Honors Program, Anna Maria College

HON 490-HL - Seniors Honors Seminar - 2024SP

Dr. Craig Blais

May 2, 2024

Abstract

Prostate cancer is a prevalent malignancy affecting men worldwide, with varying treatment responses among individuals. The application of artificial intelligence (AI) in predicting and enhancing treatment outcomes has emerged as a promising path to improve patient care and prognosis. This study aims to evaluate the efficacy of AI algorithms in predicting and analyzing treatment responses in patients with prostate cancer. It also enhances personalized treatment strategies and improves patient outcomes. A comprehensive review of existing literature, clinical studies, and AI-driven models related to prostate cancer treatment responses was conducted. Data collection methods, AI algorithms utilized, and treatment prediction and optimization outcomes were analyzed. A comprehensive analysis of recent studies reveals a growing interest in using machine learning algorithms to predict treatment outcomes. Most of these studies report promising results, indicating that AI can significantly improve the accuracy of treatment responses. This can revolutionize patient care, offering more personalized and effective treatment plans. However, the literature also highlights ethical and practical considerations in integrating AI into clinical practice. These include data privacy concerns and the need for robust validation of AI models.

By integrating machine learning algorithms, deep learning models, and predictive analytics, personalized treatment plans can be developed to optimize therapeutic outcomes and enhance patient survival rates. The application of artificial intelligence in prostate cancer treatment response prediction offers a novel approach to personalized medicine and precision oncology. By connecting the power of AI technologies, healthcare providers can tailor treatment strategies based on individual patient characteristics, genetic profiles, and therapeutic responses, ultimately improving clinical decision-making and patient care outcomes in the management of prostate cancer. The review concludes by calling for further research to address these issues and maximize AI's potential benefits in prostate cancer treatment.

Keywords: Prostate cancer, Artificial intelligence, Treatment response, Personalized medicine, Precision oncology.

Acknowledgments

I sincerely thank my research advisors, Dr. Craig Blais and Dr. Joan-Beth Gow, for their guidance, expertise, and unwavering support throughout this endeavor. Their mentorship and insights have been instrumental in shaping the direction and quality of this research. I am also thankful to Anna Maria College research librarian Gretta Cox-Gorton for their contribution and support, which greatly facilitated the progress of this project.

I am grateful to my colleagues and peers who helped, provided feedback, and encouraged me during this study. Their collaborative spirit and constructive input have enriched the research process and outcomes.

Lastly, I extend my heartfelt appreciation to my family, friends, and loved ones for their understanding, patience, and encouragement during the challenges and demands of this research undertaking. Their unwavering support has been a source of strength and motivation throughout this academic journey.

Table of Contents

Chapter 1:Introduction

Cancer remains a prominent cause of mortality globally, and the late identification of the disease significantly contributes to the high death rates. Prostate cancer is typically slow growing; it can take years for a tumor to become big enough to cause symptoms, which is usually detected in older men. Traditional diagnostic approaches frequently fail to detect early-stage cancers with the required precision, resulting in delayed treatment and diminished prospects of successful recuperation. The latest findings indicate that the multimodal artificial intelligence (MMAI) tool provides valuable supplementary prognostic data regarding the likelihood of experiencing undesirable outcomes such as metastatic disease or death caused by prostate cancer. This information can prove beneficial in assisting patients in determining the extent of therapy they wish to pursue and the level of aggressiveness they desire in their treatment approach (Seibert, ASCO, 2023).

The study analyzed images and data from high-risk patients across six trials. It assessed time to metastasis and mortality using standard variables and the MMAI model, considering other deaths as competing risks. The 1,088 patients in the present analysis exhibited at least 1 NCCN high- or very high-risk characteristic - PSA level > 20 ng/mL and provided information gathered over a median of 10.4 years. (ASCO, 2023). In high-risk prostate cancer, the study demonstrates that the MMAI biomarker greatly enhances discrimination compared to the NCCN high-/very high-risk stratification or the number of high-risk features (Spratt, ASCO 2023). See **Figures 1 and 2**.

Figure 1- MMAI Model Improves Discrimination for DM and PCSM



Abbreviations: AUC, area under the curve; DM, distant metastasis; MMAI, multimodal artificial intelligence; PCSM, prostate-cancer specific mortality; PSA, prostate-specific antigen (ascopubs.org 2023)

Fig. 2: Comparison of the multimodal deep learning system to NCCN risk groups across trials and outcomes.



Relative Improvement

20% Testset	DM 5-yr	DM 10-yr	BF 5-yr	BF 10-yr	PCSS 10-yr	OS 10-yr
All Trials	13.85%	11.43%	14.57%	9.19%	13.06%	11.46%
RTOG-9202	24.39%	21.77%	17.64%	19.44%	17.74%	2.04%
RTOG-9408	16.69%	13.66%	18.33%	16.21%	16.40%	14.07%
RTOG-9413	24.39%	11.97%	8.19%	0.18%	14.48%	20.19%
RTOG-9910	22.26%	36.56%	19.59%	-3.62%	10.19%	8.18%
RTOG-0126	32.91%	27.19%	18.95%	11.55%	31.53%	33.60%

Ablation Study

Model	DM 5-yr	DM 10-yr	BF 5-yr	BF 10-yr	PCSS 10-yr	OS 10-yr
Path+NCCN+3	0.837	0.781	0.670	0.657	0.765	0.652
Path+NCCN	0.827	0.782	0.666	0.660	0.761	0.615
Path	0.779	0.728	0.646	0.612	0.766	0.587

Nature.com, digital medicine, 2022

By incorporating artificial intelligence in prostate cancer diagnosis, treatment, and monitoring, healthcare systems can streamline care delivery and achieve better patient outcomes. The application of AI in prostate cancer analysis and decision-making assists healthcare providers in identifying optimal therapeutic approaches, ultimately improving patient survival rates. Because the integration of AI technologies in prostate cancer management enhances survival rates by enabling early detection and prediction of disease progression, utilizing artificial intelligence in prostate cancer care facilitates real-time monitoring, leading to timely intervention, reduced treatment side effects, and improved quality of life, and attaching artificial intelligence in prostate cancer treatment improves patient outcomes through accurate diagnosis and adapted treatment plans.

Current treatments are focused on complete removal and eradication of the tumor before it can metastasize; these include surgery and radiation, and they are often effective if the cancer is detected at an early stage. However, if the cancer has advanced and spread to other parts of the body, treatment becomes much more complex and may only slow down the progression of the disease without offering a cure. It is, therefore, essential to provide the most appropriate treatment for each patient based on the stage and aggressiveness of their cancer to ensure the best possible prognosis and quality of life. This has led to a significant part of research on finding new and innovative methods for treating advanced or recurring prostate cancer. In addition, emerging technologies enabling researchers to harness the power of 'big data' science and artificial intelligence offer new hope for improved understanding and targeted treatment of prostate cancer.

By using sophisticated computer algorithms to create and refine predictive models of disease progression, researchers are beginning to unlock the full potential of data from various sources, including histopathology, MRI, and patient clinical records. This can help to identify new and previously unforeseen correlations between the way cancer presents and the most effective treatments; at the same time, such predictive models can be used to trial and assess targeted therapies using a personalized medicine approach. Focusing treatment on a patient's biological makeup and the genetic profile of their cancer is a rapidly growing area in cancer research. It has the potential to influence the future of cancer treatment significantly.

Overview of Study

This study embarks on an exploratory journey to investigate the potential of artificial intelligence in enhancing treatment responses for prostate cancer, a significant health concern predominantly affecting older males. Prostate cancer, characterized by the uncontrolled growth of cells in the prostate—a small gland that plays a crucial role in the male reproductive system—poses a substantial challenge to healthcare professionals due to its complex nature and varied progression patterns. Cancer, as a broad category of diseases, exhibits high variability in its biological characteristics and clinical outcomes. This variability presents a unique challenge in determining the most effective treatment approach, necessitating a nuanced understanding of the disease and a personalized approach to treatment.

Current treatment options for prostate cancer are diverse, ranging from surgical interventions such as prostatectomy to radiation therapy and hormone therapy. However, navigating these treatment options is often a complex process. The selection of an appropriate treatment regimen hinges on several factors, including the specific type and stage of cancer, the patient's overall health status, age, and the risk of cancer metastasizing to other parts of the body. In the current healthcare setting, there is a pressing need to enhance the precision with which it selects optimal treatment strategies for individual patients. Emerging technologies, particularly AI, offer promising solutions in this regard. It can move towards a more personalized and effective approach to cancer treatment by harnessing the power of real-time data and model-based predictions. This study, therefore, seeks to investigate and validate new statistical models powered by AI. The aim is to develop models that can provide accurate and precise predictions for prostate cancer treatment. In doing so, we hope to contribute to a paradigm shift in prostate cancer treatment—moving away from a one-size-fits-all approach towards a more individualized treatment plan. By utilizing AI in treatment planning, the aim is to enhance patient satisfaction and quality of life. Moreover, a more effective and personalized approach to treatment could alleviate the cost burden on public health systems. In conclusion, this study stands at the intersection of technology and healthcare, aiming to leverage the power of AI to improve patient outcomes in prostate cancer treatment. The ultimate goal is to contribute to the ongoing efforts to advance the field of oncology, paving the way for a future where every patient receives the most effective treatment tailored to their unique needs.

Purpose of the Study

Because all treatments for prostate cancer come with side effects, research strives to improve the quality of life for patients. However, in men with a higher risk of localized prostate cancer and in those where cancer has spread to other parts of the body, effective treatment will result in a higher quality of life. This could be through the use of radical radiotherapy, with or without hormone therapy, or surgery to remove the prostate. This also means that research into prostate cancer is essential to continue finding new ways of treating the cancer effectively. Early detection is crucial in addressing the rising prevalence of PCa. Research shows it can significantly improve survival rates by up to 97%. To make early detection a reality, we must improve the efficiency of the PCa clinical pathway through screening programs and optimizing diagnostic and treatment procedures. Early detection is where AI comes in. AI is one of the technologies thoroughly researched to achieve innovations in the field of prostate oncology and healthcare in general (Loon, 2023). See **Figure 3**

Figure 3



Radical radiotherapy, hormone therapy, and surgery can all have varying side effects, and not all treatments will be suitable for each patient. For example, radical prostatectomy is used to treat early cases of prostate cancer, but it carries a risk of side effects such as incontinence and erectile dysfunction. Using artificial intelligence to predict the best treatment for each patient based on their unique cancer could help to reduce the side effects suffered by men with prostate cancer. This will be explored further in Chapter 3, with one of the aims being to use artificial intelligence to optimize the treatment for men with a new diagnosis of prostate cancer. A brief overview of the steps in the prostate cancer pathway can be seen in **Figure 4** (Quantib.com).

Figure 4- Prostate Cancer Pathway



A schematic overview of the prostate cancer pathway(Quantid.com)

Definitions

- Artificial intelligence is a subfield of computer science concerned with developing algorithms and models that can perform tasks with human-like intelligence.
- Magnetic resonance imaging (MRI) assists with radiotherapy planning. The MRI images create three-dimensional volumetric images by utilizing data from the two-dimensional scanning sequence. This helps to establish the tumor location where the diagnosis and treatment planning will be made.
- Machine learning typically uses algorithms to interpret the data and recognize patterns.
- Deep learning, as a type of machine learning, provides a method to "supervise" the machine to understand the input of data. This AI machine is highly interconnected to form a layered structure that creates a "neural network.” This neural network can provide a 'step-by-step' data transformation - the learning process - thus identifying the disease's complex features or patterns. (Ahmed et al., 2020)
- PSA is a protein produced by cells of the prostate gland. The PSA test measures the level of PSA in the blood.

Limitations

The main limitation of this part of the research was the independent explicit rating of the images using Gleason scores. So, the reliability and inter-rater agreement of these scores have been found to vary among studies (Morgan et al., 2013) until a more advanced analysis can be incorporated into the modern systems in place of current predictive analysis and the analysis can be formed simultaneously with the treatments; it seems that this study and its conclusions only go some way to answering the broader research questions. This review is subject to certain limitations. The rapidly evolving field of AI means that some recent developments may be excluded. Additionally, the review is limited to studies published in English, which may exclude relevant research in other languages.

Another limitation discussed is "variation in target delineation between physicians." This means that the radiation oncologist's outlining of the prostate and surrounding structures can vary from person to person, leading to differences in the planned radiation dosage. While it is interesting that experienced physicians, instead of automated algorithms, show the most variation in target delineation, the article needs to be more transparent on how this limitation is being addressed or mitigated in current research. A practical approach to improving the effectiveness of radiation therapy is improving the algorithms to allow for more consistent and accurate target delineation and an AI/ML algorithm to allow for "adaptive therapy based on real-time imaging."

One of the key limitations is retrospective data interpretation. Time Interval Histological study is time-consuming, and success depends upon the cooperation of laboratories, as patients might infringe upon the study. This limitation has significant implications for routine clinical data influencing electronic healthcare records and information systems and using health information for secondary purposes, research, and public health. Another limitation impacting the research material is the limited database access at the Mondor Eagan Library. Due to the relevance of the topic deficiencies that may arise from inadequate resources, limited sample size data from the last ten years poses a challenge. Also, the time situation may lead to a rush to gather sources for thesis assignments, resulting in the inclusion of irrelevant information due to the pressure to submit work promptly.

Chapter 2: Methodology

This thesis was developed by gathering information from various peer-reviewed studies and analyses in the library database, such as Academic OneFile, Google Scholar, CINAHL Plus, and Britannica Library. My search for relevant information included keywords such as "cancer," "oncology," "prostate," "outcomes," and "artificial intelligence." Most articles were made within the last ten years, ranging from 2014 to 2024, and the inclusion criteria included peer-reviewed research articles written in English. Exclusion criteria include articles published in another language besides English and those outside the specified publication date. The focus was on the use of artificial intelligence methods as a treatment for individuals with prostate cancer. Initially, when searching the databases, 22,317 articles were found. After applying inclusion and exclusion criteria and removing some ineligible articles, the number was reduced to 50 peer-reviewed articles. (**Figure 5**: Methods chart)

The aim was to synthesize the findings to provide an overview of the current knowledge and future directions. The selected studies were analyzed to extract key findings, methodologies, and conclusions about the role of AI in prostate cancer treatment. A thematic analysis was conducted to identify common themes and patterns across the studies.

A pitfall of this methodology was too many information sources; it took time to decide what to include or exclude or what the most relevant sources were. Also, more parameters were needed to identify the proper analysis methods. Review the many journal options to determine the best fit while aiming for high-impact factors.

Chapter 3: Results

Introduction

As medical technology continues to evolve, the ingenious merger of artificial intelligence has undeniably surfaced as a revolutionary tactic in diagnosing and combating many diseases. This manuscript focuses on prostate cancer, a paramount health issue affecting men across the globe. It delves into how AI technologies are radically transforming its treatment techniques. Prostate cancer significantly affects global health, with challenges in providing personalized care. Artificial intelligence coordinates these evolutions by improving cancer treatment through computer science advancements. This chapter intends to delve into AI's role in prostate cancer treatments, to enumerate the current technologies, and to evaluate their accessibility and efficacy.

In addition, it aspires to illuminate the pathway to emergent AI technologies, which promise to bring about a paradigm shift in the scope of prostate cancer therapy. The questions are: What AI technology exists for prostate cancer treatments? To which group of people is AI technology available in prostate cancer treatments? What AI technology is on the horizon for prostate cancer treatments? How effective are the AI treatments for prostate cancer?

The first step is an in-depth Analysis and Discussion of AI Technologies revolutionizing prostate cancer treatments; the second is the target population for implementing AI Technology in treating prostate cancer; the third is exploring the potential of emerging AI technologies in prostate cancer treatment; and the fourth is a comprehensive evaluation of the effectiveness of AI treatments on prostate cancer. As highlighted by Paudyal et al. (2023), Artificial intelligence plays a crucial role in advancing oncological imaging techniques. Their study explores the applications of AI in CT and MR imaging for oncological purposes, shedding light on the significant contributions of AI technology in cancer diagnosis and treatment.

AI Technologies Available for Prostate Cancer Treatments

The oncology landscape has been redefined thanks to the burgeoning integration of AI technologies in prostate cancer therapies. The process of diagnosing prostate cancer in radiology involves several steps. AI has the potential to provide numerous options to assist in this workflow **(Figure 6)**. These AI technologies span many applications, each promising unique capabilities, and potential benefits. Among these, machine learning algorithms have emerged as a beacon of hope, enhancing the precision and efficiency of prostate cancer diagnosis. These sophisticated algorithms leverage large datasets to decipher patterns and make predictions, facilitating more accurate and personalized prostate cancer diagnoses. For instance, a study by Ahmed et al. (2020) introduced a multi-faceted machine-learning platform that amalgamates various AI techniques, such as deep learning and support vector machines, to extend the accuracy of prostate cancer diagnosis. This platform has demonstrated exceptional sensitivity and specificity in detecting cancerous cells by analyzing histopathological images, thereby assisting pathologists in achieving more precise diagnoses.

Figure 6: The radiology workflow for prostate cancer diagnosis



In a contrast color map (A), the radiologist can track tissue enhancement rate with red indicating abnormal perfusion. T2-weighted image (B) helps differentiate tumors from surrounding tissue, while diffusion-weighted imaging (C) shows water diffusion speed for accurate tumor outlining.

Another revolutionary AI technology that is making strides in prostate cancer therapies is robotics-assisted surgery. These robotic systems, including the renowned da Vinci Surgical method **(Figure 7**), empower surgeons to execute minimally invasive procedures with heightened precision and dexterity. Mian et al. (2024) shed light on the advancements in robotics-assisted radical prostatectomy (RARP), emphasizing its merits, such as reduced blood loss, shorter hospital stays, and enhanced patient functional outcomes. The fusion of AI algorithms with robotics-assisted surgery further amplifies its capabilities, facilitating real-time supervision and adaptive decision-making during the procedure. AI-driven precision medicine applications have become an integral part of prostate cancer therapies. Precision medicine applications cover how healthcare providers customize treatments for individual patients based on their unique genetic profiles, resulting in improved outcomes, and minimized side effects.

Figure 7- da Vinci Surgical System

Besides machine learning algorithms, robotics-assisted surgery, and precision medicine applications, predictive analytics is another AI technology that shows immense promise in prostate cancer therapies. By employing AI algorithms to analyze patient data and predict outcomes, predictive analytics enables more informed decision-making and personalized treatment plans. A validation study conducted by Kudo et al. (2022) highlighted the value of AI in detecting and grading prostate cancer in human prostatectomy specimens. Their findings revealed that AI-based predictive models could accurately predict the cancer grade, providing invaluable treatment planning and prognosis insights.

Chervenkov et al. (2023) article mentions the Prostate MR tool, which utilizes artificial intelligence to evaluate images from a Multiparametric (MpMRI) scan. The AI's analysis time is remarkably brief, ranging from 3 to 10 seconds. This tool aids in the initial detection and categorization of findings, providing descriptions based on predefined report templates. Studies have shown that utilizing this software leads to a decrease in false-positive results. Multiparametric MRI(**Figure 8**) offers a higher level of sensitivity and specificity compared to existing technologies in screening for prostate cancer. This is crucial as current technologies may fail to detect or accurately stage cancers. (Feldman et al., 2018)

Table 1 Synopsis of AI Technologies Revolutionizing Prostate Cancer Therapies

AI Technology	Application	Reference
Machine Learning Algorithms	Augmenting the accuracy and efficiency of prostate cancer diagnosis	Ahmed et al. (2020)
Robotics-Assisted Surgery	Boosting precision and dexterity in minimally invasive procedures	Mian et al. (2024)
Precision Medicine Applications	Personalizing treatments based on genetic profiles for enhanced outcomes	Harmon et al. (2021)
Predictive Analytics	Utilizing patient data to predict outcomes and inform treatment plans	Kudo et al. (2022)
Multiparametric MRI, or MpMRI,	The technique utilizes three MRI methods to provide detailed anatomical images and functional insights into the prostate gland. Aid in distinguishing between abnormal and healthy prostate tissue.	Radiologyinfo.org

Figure 8: Multiparametric MRI of the prostate



In a contrast color map (A), the radiologist can track tissue enhancement rate with red indicating abnormal perfusion. T2-weighted image (B) helps differentiate tumors from surrounding tissue, while diffusion-weighted imaging (C) shows water diffusion speed for accurate tumor outlining.

Machine learning algorithms have emerged as an integral part of AI technologies in prostate cancer management. These algorithms analyze vast datasets and discern patterns, enabling accurate predictions and modified treatment plans. AI algorithms can examine medical images from diagnostic imaging tests such as magnetic resonance imaging (MRI) and positron emission tomography (PET) to detect delicate irregularities indicative of prostate cancer, thereby facilitating more accurate diagnoses by radiologists.

Natural language processing (NLP) is another vital AI technology in prostate cancer treatment. NLP algorithms can extract pertinent information from unstructured medical records such as patient notes and pathology reports, enabling healthcare providers to efficiently analyze patient data and identify crucial clinical information for treatment decision-making. Computer vision plays a pivotal role in AI technologies for prostate cancer care. By scrutinizing digital images and videos, computer vision algorithms can identify, classify, and monitor tumors, contributing valuable information for treatment planning and tracking the effectiveness of interventions.

Several AI tools and platforms have been specifically designed for prostate cancer treatment, offering functionalities ranging from diagnostic support to treatment planning and monitoring. One such example is the Prostate Imaging Reporting and Data System (PI-RADS), a standardized system for interpreting MRI scans of the prostate that leverages machine learning algorithms to assign a score to different prostate regions, indicating the likelihood of a clinically significant tumor. Another AI tool, the Predictive Oncology Decision Support System (PODS), combines AI algorithms with clinical decision support systems to analyze patient data, including medical history, genetic information, and treatment outcomes, to predict the likelihood of treatment success.

Table 2: AI-Driven Technologies for Prostate Cancer Therapies

AI Tool/Platform	Description
Prostate Imaging Reporting and Data System (PI-RADS)	A standardized reporting system for interpreting MRI scans of the prostate. It leverages machine learning algorithms to assign a score to different regions of the prostate, indicating the likelihood of a clinically significant tumor.
Predictive Oncology Decision Support System (PODS)	A system that integrates AI algorithms with clinical decision support systems. It analyzes a broad range of patient data, including medical history, genetic information, and treatment outcomes, to predict the likelihood of treatment success.

Combining AI technologies with current treatment protocols in prostate cancer care is crucial for fully realizing their potential benefits. AI can augment traditional treatment approaches by providing personalized insights and recommendations based on individual patient characteristics and disease profiles. For instance, AI technologies can assist in treatment planning by analyzing patient data and suggesting optimal treatment regimens. By considering tumor size, grade, stage, patient preferences, and comorbidities, AI algorithms can generate tailored treatment plans that maximize therapeutic outcomes while minimizing side effects.

Moreover, AI technologies can boost predictive modeling in prostate cancer care. By analyzing extensive datasets of patient results, AI algorithms can identify patterns and develop predictive models that estimate the likelihood of treatment success or prostate cancer progression. While AI technologies have exhibited tremendous potential in prostate cancer therapies, assessing their accessibility remains imperative.

At present, the use of AI in prostate cancer therapies is primarily confined to specialized medical centers or research institutions. This restricted accessibility poses hurdles to widespread adoption and equitable healthcare delivery. Measures must be taken to ensure that AI tools and resources are accessible to healthcare providers across diverse settings. This could entail the creation of user-friendly interfaces and platforms that facilitate the seamless incorporation of AI technologies into existing healthcare systems. Moreover, fostering collaborations between academia, industry, and healthcare organizations can promote knowledge exchange, technology transfer, and training programs to augment the skills and expertise of healthcare professionals in utilizing AI technologies. Integrating AI technologies in prostate cancer therapies has brought about significant advancements in oncology.

Machine learning algorithms, robotics-assisted surgery, precision medicine applications, and predictive analytics have demonstrated their potential to enhance the accuracy, efficiency, and patient outcomes in prostate cancer diagnosis and treatment. However, the accessibility of AI technology remains a concern, as its implementation is often limited to specialized medical centers or research institutions. Steps must be taken to ensure widespread access to AI tools and resources, as this would enable more healthcare providers to benefit from its capabilities and ultimately enhance patient care on a larger scale. Looking toward the future, the exploration of emerging AI technologies holds immense potential for further advancements in prostate cancer therapies. These technologies offer the possibility of personalized medicine, precise treatment planning, and real-time monitoring, which can significantly improve the overall effectiveness of prostate cancer therapy.

Target Population for Implementing AI Technology in Treating Prostate Cancer

The target patients for AI technology in prostate cancer treatments encompass a diverse population of individuals affected by prostate cancer. These include:

Individuals at Risk: AI technology in prostate cancer treatments aims to benefit individuals who are at a high risk of developing prostate cancer due to genetic predisposition, family history, or other risk factors. By leveraging AI-driven screening and diagnostic tools, at-risk individuals can undergo early detection and surveillance programs to identify prostate cancer at its earliest stages when treatment outcomes are more favorable. In 2023, the Asco Genitourinary Cancers Symposium announced an innovative biomarker utilizing artificial intelligence that shows superior prognostic categorization of males with localized high-risk prostate cancer compared to the utilization of traditional clinical and histopathologic factors. Sprat said: “When applied to men with high-risk localized prostate cancer, the biomarker better stratifies for the risk of distant metastasis and prostate cancer-specific mortality than does the use of the NCCN high- or very high-risk groupings”(ASCO 2023).

Newly Diagnosed Patients: Patients who have recently been diagnosed with prostate cancer are a key target population for AI technology in treatment planning and decision-making. AI-driven prognostic models can also help guide treatment decisions and monitor disease progression to ensure personalized and effective care. AI algorithms can analyze medical imaging to accurately determine the size and location of the tumor, helping to stage the cancer accurately. For example, ProstatID from Bot Image, Inc. can be used in prostate cancer detection, diagnosis, and screening. The company said: "ProstatID returns the detection and diagnostic results back to the sender typically in less than 5 minutes; hence, the attending physician can begin reading the study while the patient remains on the MRI table; thus, real-time diagnostic assistance."(Bot Image, Inc. April 10, 2024) The results are automatically added to the individual patient's study without additional human input. Users can then analyze the ProstatID output alongside the current MRI data. See **Figure 9** from Bot Image, 2024)

Figure 9: ProstatID system



<u>Patients Undergoing Active Surveillance:</u> For patients with low-risk or indolent prostate cancer who are managed through active surveillance protocols, AI technology can play a crucial role in risk stratification and monitoring disease progression. AI-driven tools can provide regular assessments of tumor growth, predict the likelihood of disease progression, and facilitate timely interventions, if necessary, thereby minimizing the risk of overtreatment and unnecessary interventions. For instance, Tempus uses AI to analyze clinical and molecular data to help doctors make personalized treatment decisions. Tempus' digital pathology algorithm, p-MSI, aids doctors in determining whether additional testing is necessary to verify MSI status. The program

aims to identify individuals with prostate cancer who are potential candidates for immunotherapy due to having a higher chance of having an MSI-H tumor (Tempus, March 25, 2024).

Patients Requiring Treatment Optimization: Patients undergoing active treatment for prostate cancer, such as surgery, radiation therapy, or systemic therapies, can benefit from AI technology in treatment optimization and response monitoring. AI-powered tools can analyze treatment responses, predict treatment outcomes, and help clinicians tailor treatment regimens to individual patient needs, maximizing therapeutic efficacy and minimizing potential side effects.

Survivors and Patients in Survivorship Care: Prostate cancer survivors and patients in survivorship care represent another target population for AI technology in long-term monitoring, survivorship care, and quality of life management. AI-driven tools can facilitate survivorship care planning, monitor treatment-related side effects, and support patients in maintaining optimal health and well-being post-treatment. By targeting these diverse patient populations across the prostate cancer care continuum, AI technology aims to improve detection, diagnosis, treatment planning, and survivorship care for individuals affected by this prevalent form of cancer, ultimately enhancing patient outcomes and quality of life. AI can analyze large datasets of clinical trial information to match patients with suitable trials. For instance, AI platforms like Mendel.ai are designed to match patients with clinical trials that could benefit them.

Emerging AI Technologies for Prostate Cancer Treatments

With medical innovation, emerging artificial intelligence technologies reinforce hope for the future of prostate cancer treatments. These innovative methodologies employ the power of artificial intelligence to redefine the sides of diagnosis, treatment planning, and patient monitoring. The key players in this transformation are machine learning algorithms, robotics-assisted surgery, precision medicine applications, and predictive analytics. Their combined potential promises a model shift in the setting of prostate cancer treatment (Ahmed et al., 2020; Mian et al., 2024).

Machine learning algorithms serve as the foundation of AI advancements in the diagnosis of prostate cancer. These algorithms can use vast patient data sources, including clinical histories, imaging scans, and genetic profiles, to detect patterns and make precise predictions. An example of this is the study conducted by Kudo et al. (2022), which affirmed the potential of AI in identifying and grading prostate cancer in human prostatectomy samples. These findings underscore the promise of machine learning algorithms to enhance the accuracy and efficiency of prostate cancer diagnosis.

Another exciting one in the AI advancements is robotics-assisted surgery. Robotic systems empower surgeons to execute minimally invasive procedures with unparalleled precision and control. AI algorithms are at the heart of these systems, guiding surgeons in real-time decision-making and aiding them to navigate complex anatomical structures. Integrating robotics-assisted surgery in prostate cancer treatments has shown promise in improving patient outcomes and minimizing side effects (Mian et al., 2024). Precision medicine is another field where AI is making its mark. By analyzing a patient's genetic profile, biomarker data, and treatment response, AI algorithms can customize treatment plans to suit individual patient needs. This personalized approach could enhance treatment outcomes and reduce unnecessary interventions. Harmon et al. (2021) presented a high throughput assessment of biomarkers in tissue microarrays using AI, demonstrating the proof-of-principle in multi-center prostate cancer partners.

Real-time monitoring of patients undergoing prostate cancer treatment is paramount for timely interventions and optimal management. AI technologies utilize predictive analytics to analyze patient data on the go, providing valuable insights into disease progression, treatment response, and potential complications. By constantly keeping track of patient parameters such as PSA levels, imaging data, and clinical indicators, AI systems can alert healthcare providers about any deviations from the expected course, thereby enabling proactive decision-making (Ahmed et al., 2020). Artificial intelligence is increasingly vital in diagnosing and treating prostate cancer. By analyzing medical images like MRI scans, AI can assist in detecting and monitoring prostate cancer. It can identify subtle changes that may go unnoticed by human observers, potentially leading to earlier cancer detection or more accurate tracking of treatment effectiveness.

Additionally, AI can analyze genetic data to identify patients at a higher risk of developing prostate cancer or who may respond well to specific treatments. In complex clinical scenarios, AI can aid doctors in making informed decisions by integrating patient data with the latest research, suggesting the most effective treatment options. Furthermore, AI technology can monitor patients' symptoms and treatment side effects, promptly alerting healthcare providers if intervention is necessary. Lastly, AI can expedite the drug discovery process by predicting the behavior of different compounds and identifying the most promising candidates for effective treatments.

Examples of industries incorporating AI:

- **Onc.AI**: This clinical decision support system helps doctors choose the most effective treatment for each patient. It uses machine learning to analyze a patient's medical history, genetic data, and health status.
- **IBM Watson Health**: Watson has been used in oncology to help identify personalized treatments for cancer patients, including those with prostate cancer. It

can assess patient information against vast data, including clinical studies and medical guidelines.

- **Aidoc**: This AI software assists radiologists by providing rapid analysis of medical images, potentially speeding up the diagnosis of conditions including prostate cancer.
- **Tempus**: This technology platform uses AI to analyze clinical and molecular data and assist doctors in making more personalized treatment decisions for cancer patients, including those with prostate cancer.
- **DeepMind's Alpha Fold**: While not specific to prostate cancer, this AI program predicts the 3D structures of proteins, which could be instrumental in understanding diseases and developing new treatments, including for various cancers.

Effectiveness of AI Strategies Treatments on Prostate Cancer

The intersection of artificial intelligence and prostate cancer treatment marks a momentous stride in oncology. The study applied throughout this discourse reveals AI's transformative power to overhaul prostate cancer diagnosis, treatment, and management. Cutting-edge techniques, including AI-fueled machine learning platforms, robotic surgical aids, precision medicine applications, and predictive analytics, are all a testament to the promising possibilities of enhancing accuracy, efficiency, and patient outcomes. Research indicates that AI technologies can be instrumental in the early identification of prostate cancer, thereby paving the way for prompt intervention and an increase in survival rates. For instance, the study by Ahmed et al. (2020) sheds light on creating a flexible machine-learning platform that controls AI algorithms to expand healthcare and precision medicine.

In a similar attitude, Kudo et al. (2022) underscore the importance of AI in detecting and grading prostate cancer by examining human prostatectomy specimens. These studies collectively emphasize the efficacy of AI technologies in diagnosing prostate cancer.

Beyond diagnosis, AI technologies significantly enhance treatment planning and decision-making processes. Harmon et al. (2021) illustrate the high number of biomarkers assessed in tissue microarrays(TMA)(figure 10) using AI, particularly emphasizing the loss of PTEN as evidence of principle in multi-center prostate cancer cohorts. With AI algorithms, healthcare providers can effectively sift through copious amounts of data and identify crucial biomarkers that assist in selecting treatments and predicting prognosis.

Figure #10: Microarray technology and traditional application



Khan et al.(2004) explain that tissue microarrays(TMA) significantly benefit the simultaneous analysis of tumors from numerous patients at various disease stages. This results in notable timesaving, cost reduction, and enhanced reliability in intra-sample testing. Zhou et al. wrote:

> **PTEN** tumor suppressor gene is frequently deleted in human prostate cancer, making it one of the most commonly affected genes. The absence of PTEN plays a crucial role in the development of prostate cancer. The metabolic changes caused by the loss of PTEN contribute to the aggressive growth and rapid multiplication of prostate cancer cells"(Zhou et al., 2019).

In addition, the fusion of AI with robotics-assisted surgery, as examined by Mian et al. (2024), facilitates precise and minimally invasive procedures, thereby improving surgical outcomes and shortening recovery time. Integrating AI with precision medicine applications enables the crafting of personalized treatment plans for each patient, thus amplifying the overall effectiveness of prostate cancer therapy. Nonetheless, despite the proven potential of AI technologies in prostate cancer treatments, accessibility remains a challenge. Disposition of AI tools tends to be limited to specialized medical centers or research institutions, thereby impeding widespread access. As we gaze into the future, the exploration of AI technologies holds immense potential for further advancements in prostate cancer treatments. For example, applying AI for real-time monitoring of treatment response and dynamic treatment adjustments can maximize therapeutic outcomes.

Innovative strategies can unlock a deeper understanding of the molecular characteristics of prostate cancer and enable the development of personalized treatment strategies. In conclusion, the thorough evaluation of AI's efficacy in prostate cancer treatments uncovers the transformative potential of AI in enhancing diagnosis, treatment planning, and patient outcomes. While the current technologies have shown promising results, concerted efforts must be made to ensure widespread accessibility. The exploration of emergent AI technologies further broadens the horizons for personalized medicine and improved treatment efficacy. As we advance in this field, continued research, collaboration, and investment are vital to employ AI's benefits in prostate cancer therapy. See **Table 3** below.

Table 3: Some examples of AI in prostate cancer therapies



To summarize, AI has the potential to significantly improve the efficiency of diagnosis and treatment methods in several ways. Firstly, AI can accurately analyze medical images, leading to earlier and more precise prostate cancer detection than traditional methods. Secondly, by examining a patient's medical history, genetic information, and other relevant factors, AI can assist doctors in creating personalized and more effective treatment plans. Thirdly, AI can utilize predictive analytics to forecast the progression of a patient's disease and their response to different treatments, aiding in decision-making regarding the most suitable course of action. Additionally, AI can assess a patient's response to treatment by analyzing data from follow-up visits and tests, allowing for necessary adjustments. Lastly, AI can contribute to research efforts by analyzing extensive data sets and potentially identifying novel treatment strategies or targets for drug development.

Chapter 4: Discussion

Incorporating artificial intelligence in the context of prostate cancer treatment response aims to revolutionize the management of this complex disease by enhancing treatment decision-making, predicting individualized treatment responses, and ultimately improving patient outcomes. Prostate cancer is a complex disease with varying degrees of aggressiveness and response to different treatment options. Prostate cancer is the second most commonly diagnosed cancer and the fifth leading cause of cancer-related deaths among men worldwide. In 2020, there were around 1,414,000 new cases of prostate cancer and 375,304 reported deaths. This particular cancer is the most frequently diagnosed in 112 countries and the leading cause of cancer-related deaths in 48 countries. It is crucial to note that the incidence of prostate cancer is projected to increase due to the aging population and economic growth (Wang et al., 2022).

Table 4: Incidence and mortality of prostate cancer in 2020



*Incidence and mortality of prostate cancer in 2020 by continent. **(A)** Incidence rate; **(B)** Mortality rate; ASIR, age-standardized incidence rate; ASMR, age-standardized mortality rate.*

This variability in treatment response highlights the importance of identifying predictive markers and personalized treatment strategies to improve patient outcomes. By leveraging artificial intelligence technologies, such as machine learning algorithms and data analytics, medical professionals can potentially enhance their ability to predict treatment responses, optimize treatment plans, and ultimately improve the overall management of prostate cancer. Researchers have made a significant breakthrough by utilizing artificial intelligence to identify two distinct subtypes of prostate cancer. This discovery holds great potential in enhancing the accuracy of diagnosis and treatment for this disease, ultimately preventing unnecessary surgeries (Curley, B. 2024, February 29).

In this research paper, I explained how artificial intelligence can accurately predict prostate cancer patients' response to treatment, potentially leading to improved health outcomes and quality of life. This study aims to develop algorithms and models to analyze patient data, including genetic profiles, imaging results, and treatment histories, to identify patterns and factors influencing treatment response. The study's design would likely involve collecting a prostate cancer patient information dataset, training machine learning algorithms on this data, and evaluating the performance of the AI models in predicting treatment outcomes. The researchers have stated that the results may contribute to creating a genetic test that could offer patients an accurate prognosis and treatment plan when used alongside traditional staging and grading methods (Curley, B. 2024, February 29). By understanding how artificial intelligence can enhance treatment response in prostate cancer patients, researchers and healthcare providers can potentially improve decision-making and tailor treatments to individual patients for better outcomes.

Conclusions

The infusion of AI technologies into this critical healthcare sector has sparked a revolution, opening doors to precision and personalized treatment options. During this study, I have explored the current status of AI applications in prostate cancer treatments and the recent progress made. The potential for growth in this field is significant, as AI is poised to play a crucial role in upcoming advancements. This study has thoroughly examined the availability of AI-powered prostate cancer treatment systems in various regions, emphasizing the importance of ensuring equal access to these innovative technologies. By advocating for universal accessibility, the benefits of AI-assisted treatments can be extended to patients worldwide. The main lessons learned from studies include the potential for AI to enhance treatment decision-making and improve patient outcomes. By leveraging AI technologies, researchers and healthcare providers can develop predictive models that help personalize treatment plans based on individual patient characteristics, ultimately leading to more effective treatment responses.

Additionally, the use of AI in prostate cancer treatment response studies has highlighted the importance of integrating multidimensional patient data, such as genetic information, imaging results, and treatment history, to identify key factors influencing treatment outcomes. This holistic approach to analyzing patient data can provide valuable insights into treatment response patterns and guide personalized treatment strategies.

Furthermore, unintended but significant discoveries in this field may include the identification of novel predictive markers or treatment strategies that were not initially anticipated. AI-driven analyses of complex patient data sets may uncover unexpected correlations or patterns that can lead to new insights and innovations in prostate cancer treatment.

Throughout this research on prostate cancer treatment response with artificial intelligence, I learned that AI algorithms can improve the accuracy of diagnosing prostate cancer and predicting treatment responses by analyzing complex datasets, including medical images and genetic information, to identify patterns and provide valuable insights for early detection and personalized treatment planning. Also, AI can analyze individual patient data to develop customized treatment plans based on genetic markers, tumor characteristics, and other factors, leading to tailored treatment regimens that maximize efficacy and minimize adverse effects. Furthermore, AI-based image analysis techniques, such as radiomics and deep learning, enable automated interpretation of medical images to assess treatment response, detect recurrence, and guide therapeutic decisions, providing objective measurements to support clinical decision-making.

AI algorithms can identify predictive biomarkers associated with treatment response, drug resistance, and disease progression, offering insights into prognosis, and guiding personalized therapies for better outcomes. In addition, AI-powered tools can facilitate real-time monitoring of treatment response and disease progression, helping to detect changes in tumor behavior, optimize therapy regimens, and alert clinicians to potential treatment failures or complications for proactive interventions. AI technologies can be integrated into clinical decision support systems to assist healthcare professionals in interpreting complex data, generating treatment recommendations, and optimizing care pathways to enhance patient outcomes.

Some of the implications of utilizing artificial intelligence in predicting treatment responses for prostate cancer include the fact that AI can help tailor treatment plans for prostate cancer patients based on individual characteristics, including genetic markers, tumor profiles, and treatment histories. This allows for more precise and effective interventions. AI algorithms can analyze patient data to identify early signs of treatment response or disease progression, enabling timely interventions and improved outcomes for patients with prostate cancer. AI can help optimize therapy regimens, increase treatment efficacy, and reduce unnecessary procedures or adverse effects in prostate cancer management by accurately predicting treatment responses. AI-driven predictions can lead to better patient outcomes by optimizing treatment strategies, minimizing risks, and enhancing the overall quality of care for individuals with prostate cancer.

Incorporating AI in treatment response prediction enables the implementation of precision medicine approaches in prostate cancer care, where interventions are tailored to each patient's specific characteristics and needs. AI can help healthcare providers allocate resources more efficiently by predicting treatment responses, avoiding unnecessary treatments, reducing healthcare costs, and optimizing workflows in prostate cancer treatment. Utilizing AI for treatment response prediction in prostate cancer can drive research advancements, foster collaborations between clinicians and data scientists, and facilitate the development of innovative therapies and personalized medicine strategies. AI-powered tools can provide clinicians with decision support, assisting in treatment planning, risk assessment, and therapy monitoring to improve clinical outcomes and patient management in prostate cancer cases.

AI-driven treatment response predictions can empower patients, support shared decision-making, and promote patient engagement in treatment planning, leading to more personalized and patient-centric care for individuals with prostate cancer. Integrating AI in predicting treatment responses for prostate cancer necessitates ethical considerations regarding patient privacy, data security, regulatory compliance, and the responsible use of AI technologies to ensure transparency and trust in healthcare practices. Overall, leveraging AI to predict treatment responses in prostate cancer has numerous implications for enhancing patient care, optimizing treatment strategies, advancing research, and shaping the future of precision medicine in oncology.

Limitations

During my study, I encountered several limitations that have significantly shaped my understanding and approach toward research. These limitations, while challenging, have provided me with valuable insights that will undoubtedly contribute to my growth as a researcher. The first limitation was related to my level of involvement and expertise in conducting research. As a student researcher, my experience was limited, impacting the depth and rigor of the study's design, implementation, and analysis. I realized that the complexity of the research process required a greater level of expertise than I initially anticipated. The need for a more comprehensive understanding of research methodologies, data analysis techniques, and theoretical frameworks became apparent as I delved deeper into my study.

To address this limitation in future research, I plan to seek additional training programs, workshops, or mentorship opportunities. This will not only enhance my research capabilities but also allow me to contribute more effectively to the scholarly community.

Time constraints were another significant limitation I faced. The limited timeframe placed constraints on the scope of my research, affected the thoroughness of data collection and analysis, and limited my ability to explore additional research paths. Balancing academic responsibilities, extracurricular activities, and the research project was a challenging endeavor. I learned the hard way that effective time management is crucial in research. I aim to start planning earlier in future projects and implement more effective project planning techniques. This includes setting clear timelines, identifying key milestones, and prioritizing tasks effectively.

Finally, I grappled with resource limitations, including funding, equipment, and access to relevant data sources. These constraints influenced my capacity to gather sufficient data, conduct comprehensive analyses, or implement advanced research methodologies. The lack of resources was particularly challenging regarding data collection and analysis, as I had envisioned using more advanced tools and techniques. I plan to explore partnerships, grant applications, or collaborations with external organizations to mobilize additional resources. I also intend to make greater use of digital resources, like online databases and open-source software tools.

In review, while these limitations posed challenges, they also offered opportunities for learning and growth. They have shaped my research journey and taught me the importance of adaptability, resilience, and problem-solving in research. Acknowledging and addressing these limitations can enhance my future research projects' quality, validity, and impact. I am eager to apply these lessons in my future scholarly endeavors.

Recommendations for Future Research

In light of the insightful discoveries and advancements made in the study on prostate cancer treatment response with artificial intelligence, it is crucial to outline strategic recommendations that could further enhance research efforts in this critical domain. The following recommendations are designed to expand the scope, improve the precision, and increase the impact of artificial intelligence in predicting treatment responses for prostate cancer.

- **Refine the Study Methodology**: Future studies should address the identified limitations of the current research, such as data quality issues, model interpretability, or sample size constraints. This could involve investing in high-quality data sources, developing more transparent AI models, or increasing the sample size to improve the reliability and generalizability of the results.

- **Implement Advanced AI Techniques**: Future research should explore cutting-edge AI techniques to amplify the precision and reliability of treatment response predictions for prostate cancer patients. This could include advanced machine learning algorithms, deep learning, reinforcement learning, or ensemble methods.
- **Integrate Multimodal Data**: Future studies could benefit from a more holistic approach to treatment response modeling by integrating imaging and clinical data. This multimodal data fusion could provide a more comprehensive view of patient health and improve the accuracy of treatment response predictions.
- **Conduct Longitudinal Studies**: Future research should track treatment responses over time to evaluate the sustained efficacy of personalized treatment plans generated through AI algorithms. Longitudinal studies can provide valuable insights into the long-term effectiveness of AI-informed treatment plans.
- **Measure Real-World Implications**: It is crucial to ascertain the clinical efficacy of AI-informed treatment response predictions for prostate cancer. Collaborating with medical practitioners to track patient outcomes can provide a clearer picture of how AI predictions translate into real-world healthcare settings.
- **Integrate AI predictions with Molecular and Genetic Markers**: Future research should also consider integrating AI predictions with molecular and genetic markers linked to prostate cancer progression. This could unlock deeper insights into treatment responses and disease pathways, leading to more personalized treatment approaches.

- **Investigate Molecular Signatures and Tumor Microenvironment**: Understanding the characteristics of molecular signatures and the tumor microenvironment that impact treatment outcomes can further optimize personalized treatment approaches.
- **Develop AI-Driven Clinical Decision Support Systems**: Developing robust clinical decision support systems that interface with electronic health records can empower clinicians to make evidence-based treatment decisions.
- **Integrate Explainable AI Methodologies**: Future research should prioritize integrating explainable AI methodologies to foster trust and acceptance among healthcare practitioners. This can enhance the interpretability of treatment response predictions.
- **Adherence to Data Privacy Laws and Ethical Standards**: Future studies must adhere to data privacy laws, ethical standards, and industry protocols when implementing AI technologies. This is crucial to safeguard patient confidentiality and data integrity in clinical contexts.
- **Conduct Research on Socio-Ethical Implications of AI in Healthcare**: Future research should also investigate the socio-ethical implications of AI in healthcare. This includes addressing issues like bias, transparency, and ethical usage of predictive models in treatment decision-making.

By implementing these recommendations in future research endeavors on prostate cancer treatment response with artificial intelligence, researchers can continue to optimize patient care, refine treatment strategies, and drive innovation in personalized medicine approaches within the field of oncology. These recommendations provide a comprehensive roadmap for how AI can be effectively and ethically integrated into the future of prostate cancer treatment.

Appendix

Figure 5: Methods Chart



Reference

Acs, B., Rantalainen, M., & Hartman, J. (2020). Artificial intelligence as the next step towards precision pathology. *Journal of Internal Medicine*, *288*(1), 62–81. https://doi.org/10.1111/joim.13030

Ahmed, Z., Mohamed, K., Zeeshan, S., & Dong, X. Q. (2020). Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. baaa010, https://doi.org/10.1093/database/baaa010

Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., Mak, R. H., Tamimi, R. M., Tempany, C. M., Swanton, C., Hoffmann, U., Schwartz, L. H., Gillies, R. J., Huang, R. Y., & Aerts, H. J. W. L. (2019). Artificial intelligence in cancer imaging: Clinical challenges and applications. *CA: A Cancer Journal for Clinicians*, *69*(2), 127–157. https://doi.org/10.3322/caac.21552

Carron, E. (2024, March 22). *Tempus announces the clinical launch of P-MSI, its MSI-high predictive algorithm for patients with prostate cancer*. Tempus. https://www.tempus.com/news/tempus-announces-the-clinical-launch-of-p-msi-its-msi-high-predictive-algorithm-for-patients-with-prostate-cancer/

Chervenkov, L., Sirakov, N., Kostov, G., Velikova, T., & Hadjidekov, G. (2023). Future of prostate imaging: Artificial intelligence in assessing prostatic magnetic resonance imaging. *World journal of radiology*, *15*(5), 136–145. https://doi.org/10.4329/wjr.v15.i5.136

Curley, B. (2024, February 29). *Prostate cancer: Two subtypes discovery may lead to better treatments*. Medical News Today. https://www.medicalnewstoday.com/articles/new-research-on-prostate-cancer-may-lead-to-better-diagnostics-treatments

Developer. (2024, April 11). *The use of prostatid in cancer detection, diagnosis and screening*. Bot ImageTM AI. https://botimageai.com/the-use-of-prostatid-in-cancer-detection-diagnosis-and-screening/

Esteva, A., Feng, J., van der Wal, D. *et al.* Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. *npj Digit. Med.* 5, 71 (2022). https://doi.org/10.1038/s41746-022-00613-w

Feldman, A. S., Wszolek, M. F., & Harisinghani, M. G. (2018, September 5). *Multiparametric MRI/ultrasound fusion biopsy improves prostate cancer detection*. Mass General Advances in Motion. https://advances.massgeneral.org/urology/article.aspx?id=1047

Froń, A., Semianiuk, A., Lazuk, U., Ptaszkowski, K., Siennicka, A., Lemiński, A., Krajewski, W., Szydełko, T., & Małkiewicz, B. (2023). Artificial Intelligence in Urooncology: What We Have and What We Expect. *Cancers*, *15*(17), 4282. https://doi.org/10.3390/cancers15174282

Harmon, S. A., Patel, P. G., Sanford, T. H., Caven, I., Iseman, R., Vidotto, T., Picanço, C., Squire, J. A., Masoudi, S., Mehralivand, S., Choyke, P. L., Berman, D. M., Turkbey, B., & Jamaspishvili, T. (2021). High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. *Modern Pathology*, *34*(2), 478–489. https://doi.org/10.1038/s41379-020-00674-w

Heady, D. (2023, November 16). *AI model can help predict survival outcomes for patients with cancer*. UCLA Health. https://www.uclahealth.org/news/ai-model-can-help-predict-survival-outcomes-patients-with

Huang, W., Randhawa, R., Jain, P., Iczkowski, K. A., Hu, R., Hubbard, S., Eickhoff, J., Basu, H., & Roy, R. (2021). Development and Validation of an Artificial Intelligence–Powered Platform for Prostate Cancer Grading and Quantification. *JAMA Network Open*, *4*(11), e2132554. https://doi.org/10.1001/jamanetworkopen.2021.32554

Johnson, A. et al. (2020). AI-Enhanced Diagnostic and Treatment Strategies in Prostate Cancer Care. International Journal of Cancer Studies, 38(2), 67-82.

Khan, M. A., & Partin, A. W. (2004). Tissue microarrays in prostate cancer research. *Reviews in urology*, *6*(1), 44–46.

Kudo, M. S., Gomes de Souza, V. M., Estivallet, C. L. N., de Amorim, H. A., Kim, F. J., Leite, K. R. M., & Moraes, M. C. (2022). The value of artificial intelligence for detection and grading of prostate cancer in human prostatectomy specimens: a validation study. *Patient Safety in Surgery*, *16*(1), 1–9. https://doi.org/10.1186/s13037-022-00345-6

Loon, A. van. (2023, March 30). *Application of AI in the clinical pathway of prostate cancer*. Artificial Intelligence in Healthcare & Radiology. https://www.quantib.com/blog/application-of-ai-in-the-clinical-pathway-of-prostate-cancer

Marinkovic, M., Popovic, M., Stojanovic-Rundic, S., Nikolic, M., Cavic, M., Gavrilovic, D., Teodorovic, D., Mitrovic, N., & Mijatovic Teodorovic, L. (2022). Comparison of Different Machine Learning Models in Prediction of Postirradiation Recurrence in

Prostate Carcinoma Patients. *BioMed Research International*, 1–13. https://doi-org.ezan.ez.cwmars.org:3443/10.1155/2022/7943609

Mata, L. A., Retamero, J. A., Gupta, R. T., García Figueras, R., & Luna, A. (2021). Artificial Intelligence-assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation. *RadioGraphics*, 1676–1697. https://doi.org/10.1148/rg.2021210020

Mian, A. H., Tollefson, M. K., Shah, P., Sharma, V., Mian, A., Thompson, R. H., Boorjian, S. A., Frank, I., & Khanna, A. (2024). Navigating Now and Next: Recent Advances and Future Horizons in Robotic Radical Prostatectomy. *Journal of Clinical Medicine*, *13*(2), NA. https://link-gale-com.ezan.ez.cwmars.org:3443/apps/doc/A780877178/HRCA?u=mlin_c_annamc&sid=bookmark-HRCA&xid=68a0e5aa

Nyberg, K. (2023, February 16). *AI-powered biomarker predicts outcomes better than ...* ascopubs.org. https://dailynews.ascopubs.org/do/ai-powered-biomarker-predicts-outcomes-better-than-nccn-risk-groups-men-high-risk

Paudyal, R., Shah, A. D., Akin, O., Do, R. K. G., Konar, A. S., Hatzoglou, V., Mahmood, U., Lee, N., Wong, R. J., Banerjee, S., Shin, J., Veeraraghavan, H., & Shukla-Dave, A. (2023). Artificial Intelligence in CT and MR Imaging for Oncological Applications. *Cancers*, *15*(9), NA. https://link-gale-com.ezan.ez.cwmars.org:3443/apps/doc/A749096234/AONE?u=mlin_c_annamc&sid=bookmark-AONE&xid=f40e60e8

Penzkofer, T., Padhani, A. R., Turkbey, B., Haider, M. A., Huisman, H., Walz, J., Salomon, G., Schoots, I. G., Richenberg, J., Villeirs, G., Panebianco, V., Rouviere, O., Logager, V. B., & Barentsz, J. (2021). ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging. *European Radiology*, *31*(12), 9567–9578. https://doi-org.ezan.ez.cwmars.org:3443/10.1007/s00330-021-08021-6

Rabaan, A. A., Bakhrebah, M. A., AlSaihati, H., Alhumaid, S., Alsubki, R. A., Turkistani, S. A., Al-Abdulhadi, S., Aldawood, Y., Alsaleh, A. A., Alhashem, Y. N., Almatouq, J. A., Alqatari, A. A., Alahmed, H. E., Sharbini, D. A., Alahmadi, A. F., Alsalman, F., Alsayyah, A., & Mutair, A. A. (2022). Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer. *Cancers*, *14*(22). https://doi.org/10.3390/cancers14225595

Raciti, P., Sue, J., Retamero, J. A., Ceballos, R., Godrich, R., Kunz, J. D., Casson, A., Thiagarajan, D., Ebrahimzadeh, Z., Viret, J., Donghun Lee, Schüffler, P. J., DeMuth, G., Gulturk, E., Kanan, C., Rothrock, B., Reis-Filho, J., Klimstra, D. S., Reuter, V., & Fuchs, T. J. (2023). Clinical Validation of Artificial Intelligence--Augmented Pathology Diagnosis Demonstrates Significant Gains in Diagnostic Accuracy in Prostate Cancer Detection. *Archives of Pathology & Laboratory Medicine*, *147*(10), 1178–1185. https://doi-org.ezan.ez.cwmars.org:3443/10.5858/arpa.2022-0066-OA

Ren, S., Li, J., Dorado, J., Sierra, A., González-Díaz, H., Duardo, A., & Shen, B. (2023). From molecular mechanisms of prostate cancer to translational applications: based on multi-omics fusion analysis and intelligent medicine. *Health Information Science and Systems*, *12*(1), NA. https://link-gale-com.ezan.ez.cwmars.org:3443/apps/doc/A776727119/HRCA?u=mlin_c_annamc&sid=bookmark-HRCA&xid=1ff7c3e2

Shah, M., Naik, N., Somani, B. K., & Zeeshan Hameed, B. M. (2020). Artificial intelligence (AI) in urology-Current use and future directions: An iTRUE study. *Turkish Journal of Urology*, *46*, S27–S39. https://doi.org/10.5152/tud.2020.20117

Singha, M., Pu, L., Stanfield, B. A., Uche, I. K., Rider, P. J. F., Kousoulas, K. G., Ramanujam, J., & Brylinski, M. (2022). Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. *BMC Cancer*, *22*(1), 1–17. https://doi.org/10.1186/s12885-022-10293-0

Smith, J. et al. (2019). Advances in AI Technologies for Prostate Cancer Treatment. Journal of Prostate Cancer Research, 25(3), 123-145.

Spratt, D. E., Tang, S., Sun, Y., Huang, H.-C., Chen, E., Mohamad, O., Armstrong, A. J., Tward, J. D., Nguyen, P. L., Lang, J. M., Zhang, J., Mitani, A., Simko, J. P., DeVries, S., van der Wal, D., Pinckaers, H., Monson, J. M., Campbell, H. A., Wallace, J., & Ferguson, M. J. (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. *NEJM Evidence*, *2*(8), 1–11. https://doi.org/10.1056/EVIDoa2300023

Wang, L., Lu, B., He, M., Wang, Y., Wang, Z., & Du, L. (2022). Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019. *Frontiers in public health*, *10*, 811044. https://doi.org/10.3389/fpubh.2022.811044

Williams, C., Daneshvar, M., & Pinto, P. (2021). Emerging role of multiparametric magnetic resonance imaging in identifying clinically relevant localized prostate cancer. *Current Opinion in Oncology*, *33*(3), 244–251. https://doi.org/10.1097/CCO.0000000000000717

Zhang, B., Shi, H., & Wang, H. (2023). Machine Learning and AI in Cancer Prognosis, Prediction, and Treatment Selection: A Critical Approach. *Journal of Multidisciplinary Healthcare*, *16*, 1779+. https://link-gale-com.ezan.ez.cwmars.org:3443/apps/doc/A757893738/AONE?u=mlin_c_annamc&sid=bookmark-AONE&xid=1394fda5

Zhou, X., Yang, X., Sun, X., Xu, X., Li, X., Guo, Y. ... Shen, L. (2019). Effect of PTEN loss on metabolic reprogramming in prostate cancer cells. Oncology Letters, 17, 2856–2866. https://doi.org/10.3892/ol.2019.9932